Inferra AIResearch Tools

Inferra AI / Company / PNTG

Pennant Group, Inc.

PNTG · Health Care

Last earnings Aug 5, 2026

AI analysis

Q2 2025 · reported Dec 17, 2025

Based on: Earnings release + parent 8-K/A + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Outlook statement

“2026 Guidance Update Management is providing updating 2026 annual guidance as follows total revenue is anticipated to be between $1,171.1 million and $1,190.1 million full year 2026 adjusted earnings per diluted share is anticipated to be between $1.34 and $1.41 full year 2026 adjusted EBITDA is anticipated to be between $94.4 million and $98.0 million and full year adjusted EBITDA prior to NCI is anticipated to be $101.5 million to $105.1 million.”

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Represents an adjustment to long-term debt to reflect the $146.5 million cash proceeds from borrowings under the Company s Amended and Restated Credit Agreement (the Credit Facility ).

Represents a $4.6 million and $12.8 million increase to interest expense, net for the six months ended June 30, 2025, and the year ended December 31, 2024, respectively, resulting from interest on the new debt.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Pennant Group, Inc. Q2 2025 results

Based on: Earnings release + parent 8-K/A + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Represents an adjustment to long-term debt to reflect the $146.5 million cash proceeds from borrowings under the Company s Amended and Restated Credit Agreement (the Credit Facility ).

SEC original ↗Pennant Group, Inc. — Earnings release (8-K exhibit)EX-99Dec 17, 2025

Represents a $4.6 million and $12.8 million increase to interest expense, net for the six months ended June 30, 2025, and the year ended December 31, 2024, respectively, resulting from interest on the new debt.

SEC original ↗Pennant Group, Inc. — Earnings release (8-K exhibit)EX-99Dec 17, 2025

The Company calculated the lease liability based on the remaining lease payments and the Company s incremental borrowing rate on the Closing Date.

SEC original ↗Pennant Group, Inc. — Earnings release (8-K exhibit)EX-99Dec 17, 2025

The CODM does not review assets by segment and therefore assets and capital expenditure by segment are not disclosed below.

SEC original ↗Pennant Group, Inc. — 10-Q Quarterly report10-QAug 5, 2026

In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at each lease s commencement date to determine each lease's operating lease liability.

SEC original ↗Pennant Group, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Strategy & priorities

ACQUISITIONS The Company s acquisition focus is to purchase or lease operations that are complementary to the Company s current businesses, accretive to the Company s business, or otherwise advance the Company s strategy.

SEC original ↗Pennant Group, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Risks & headwinds

Legal Proceedings 49 Item 1A.

SEC original ↗Pennant Group, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The Company has determined that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors.

SEC original ↗Pennant Group, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

30 documents

Earnings releases

14 documents

Presentations

0 documents

No presentations for Pennant Group, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Pennant Group, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.